Results 111 to 120 of about 3,116,614 (307)

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. [PDF]

, 2018
Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops.
Amicone, Laura, Marchetti, Alessandra
core   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W, Faltermeier, Claire, Zarrinpar, Ali   +2 more
core   +2 more sources

Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib

Cell Death and Disease
Mitochondrial damage-associated molecular patterns (DAMPs) including mitochondrial DNA (mtDNA), TFAM (transcription factor A, mitochondrial), and ATP, which play crucial roles in the regulation of inflammatory environment in human diseases.
Qi Yang, Mengmeng Cui, Jiaxin Wang, Yuan Zhao, Weitao Yin, Z. Liao, Yixuan Liang, Zhixiong Jiang, Yujia Li, Jinrong Guo, Lixia Qi, Jiaxing Chen, Jing Zhao, D. Bao, Z. Xu   +14 more
semanticscholar   +1 more source

NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis

Cancer Science, 2023
NR0B1 is frequently activated in hepatocellular carcinoma (HCC). However, the role of NR0B1 is controversial in HCC. In this study, we observed that NR0B1 was an independent poor prognostic factor, negatively correlated with the overall survival of HCC ...
X. Tan, Zhaokun Wang, Shunyao Liao, Ming Yi, D. Tao, Xinyue Zhang, Xiang-you Leng, Jiaying Shi, Shengyu Xie, Yuan Yang, Y. Liu   +10 more
semanticscholar   +1 more source

Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth

Scandinavian Journal of Gastroenterology, 2017
Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This study investigated the inhibitory effect of sorafenib on xenograft models of gastric cancer cells and 5-fluorouracil (5-FU)-resistant cells.The half-maximal inhibitory concentration (IC50) of sorafenib in NCI-N87 cells was determined.
Hee Man, Kim, Sun A, Kim, Soo Been, Park, Jae Hee, Cho, Si Young, Song   +4 more
openaire   +3 more sources

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance [PDF]

, 2013
Acquired resistance towards sorafenib treatment was found in HCC patients, which results in poor prognosis. To investigate the enhanced metastatic potential of sorafenib resistance cells, sorafenib-resistant (SorR) cell lines were established by long ...
Cheng, Nathan Shiu Man, Chow, Ariel Ka Man, Lam, Colin Siu Chi, Ng, Lui, Pang, Roberta Wen Chi, Poon, Ronnie Tung Ping, Wan, Timothy Ming Hun, Wong, Sunny Kit Man, Yau, Thomas Chung Cheung   +8 more
core   +3 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BMC Cancer, 2017
Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high.
Yinzong Xiao, Lunquan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xue-Gong Fan   +9 more
doaj   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources